European Journal of Medicinal Chemistry (2020)
Update date:2022-08-03
Topics:
Schoepf, Anna M.
Salcher, Stefan
Obexer, Petra
Gust, Ronald
Recent studies examined the possibility to overcome imatinib resistance in chronic myeloid leukemia (CML) patients by combination therapy with peroxisome proliferator-activated receptor gamma (PPARγ) ligands. Pioglitazone, a full PPARγ agonist, improved the survival of patients by the gradual elimination of the residual CML stem cell pool. To evaluate the importance of the pharmacological profile of PPARγ agonists on the ability to circumvent resistance, the partial PPARγ agonist 4‘-((2-propyl-1H-benzo[d]imidazol-1-yl)methyl)-[1,1’-biphenyl]-2-carboxylic acid, derived from telmisartan, and other related derivatives were investigated. The 4-substituted benzimidazole derivatives bearing a [1,1′-biphenyl]-2-carboxamide moiety sensitized K562-resistant cells to imatinib treatment. Especially the derivatives 18a-f, which did not activate PPARγ to more than 40% at 10 μM, retrieved the cytotoxicity of imatinib in these cells. The cell death modulating properties were higher than that of pioglitazone. It is of interest to note that all novel compounds were not cytotoxic neither on non-resistant nor on resistant cells. They exerted antitumor potency only in combination with imatinib.
View MoreShandong Topscience Biotech Co., Ltd.
Contact:0633-2619278
Address:No. 98 Lanshan West Road, Lanshan District, Rizhao, Shandong Province, P.R. of China
Synochem Ingredients Corp., Ltd.
Contact:+86-512-5636 2180
Address:Zhangjiagang Free Trade Zone
Yueyang Hudex Pharmaceuticals Ltd.
Contact:0730-8748800
Address:Wujiang Bridge,Yueyang Economy & Technology Development Zone
Hangzhou Donglou Bio-nutrient Co., Ltd.
Contact:+86-571-82225795,13967112289
Address:Louta Town, Xiaoshan,Hangzhou,Zhejiang
Chengdu Pukang Biotechnology Co., Ltd
Contact:+86-28-82550498
Address:No. 558 Rulin Road,Xinjin county,Chengdu city, China
Doi:10.1021/jm900305z
(2009)Doi:10.1016/j.tetlet.2008.04.065
(2008)Doi:10.1055/s-2008-1066993
(2008)Doi:10.1016/j.tetlet.2008.04.017
(2008)Doi:10.1002/jhet.5570220414
(1985)Doi:10.1016/j.bmcl.2020.127249
(2020)